Name: Paclitaxel

---

Type: small molecule

---

Groups: approved

---

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

---

Accession Number: DB01229 ( APRD00259, DB05261, DB05927)

---

Description: Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a US National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. Later it was discovered that endophytic fungi in the bark synthesize paclitaxel. When it was developed commercially by Bristol-Myers Squibb (BMS), the generic name was changed to paclitaxel and the BMS compound is sold under the trademark Taxol. In this formulation, paclitaxel is dissolved in Kolliphor EL and ethanol, as a delivery agent. A newer formulation, in which paclitaxel is bound to albumin, is sold under the trademark Abraxane. [Wikipedia]

---

Structure:

---

Prescription Products:

Name	Dosage	Strength	Route	Marketing Start	Marketing End	Country
Abraxane	injection, powder, lyophilized, for suspension	100 mg/20mL	intravenous	10-02-2005		US
Abraxane for Injectable Suspension	powder for suspension	100 mg	intravenous	31-08-2006		Canada
Aj-paclitaxel	solution	6 mg	intravenous	01-01-1970		Canada
Paclitaxel	injection	6 mg/mL	intravenous	11-07-2013		US
Paclitaxel	injection	6 mg/mL	intravenous	11-07-2013		US
Paclitaxel	injection	6 mg/mL	intravenous	11-07-2013		US
Paclitaxel	liquid	6 mg	intravenous	01-01-1970		Canada
Paclitaxel for Injection	solution	6 mg	intravenous	01-01-1970		Canada
Paclitaxel for Injection	solution	6 mg	intravenous	31-10-2001		Canada
Paclitaxel for Injection	solution	6 mg	intravenous	17-12-2007		Canada
Paclitaxel for Injection USP	solution	6 mg	intravenous	22-02-2011		Canada
Paclitaxel Injection	liquid	6 mg	intravenous	01-01-1970		Canada
Paclitaxel Injection	liquid	6 mg	intravenous	24-10-1997	06-12-2005	Canada
Paclitaxel Injection USP	solution	6 mg	intravenous	02-07-2014		Canada
Paclitaxel Injection USP	solution	6 mg	intravenous	31-03-2015		Canada
Paclitaxel Injection, USP	solution	6 mg	intravenous	01-01-1970		Canada
Paxene	liquid	6 mg	intravenous	01-01-1970		Canada
Taxol	solution	6 mg	intravenous	31-12-1993	20-07-2012	Canada
Teva-paclitaxel for Injection	liquid	6 mg	intravenous	01-01-1970		Canada

---

Generic Prescription Products:

Name	Dosage	Strength	Route	Marketing Start	Marketing End	Country
Apo-paclitaxel Injectable	solution	6 mg	intravenous	07-02-2005		Canada
Paclitaxel	injection, solution	6 mg/mL	intravenous	20-03-2009		US
Paclitaxel	injection	300 mg/50mL	intravenous	30-09-2011		US
Paclitaxel	injection	100 mg/16.7mL	intravenous	30-09-2011		US
Paclitaxel	injection, solution, concentrate	6 mg/mL	intravenous	03-11-2009		US
Paclitaxel	injection, solution, concentrate	6 mg/mL	intravenous	24-09-2008		US
Paclitaxel	injection, solution, concentrate	6 mg/mL	intravenous	23-10-2008		US
Paclitaxel	injection, solution, concentrate	6 mg/mL	intravenous	16-09-2009		US
Paclitaxel	injection	30 mg/5mL	intravenous	30-09-2011		US
Paclitaxel	injection	100 mg/16.7mL	intravenous	30-09-2011		US
Paclitaxel	injection	300 mg/50mL	intravenous	30-09-2011		US
Paclitaxel	injection	30 mg/5mL	intravenous	30-09-2011		US
Paclitaxel	injection, solution	6 mg/mL	intravenous	27-09-2011		US
Paclitaxel	injection, solution	6 mg/mL	intravenous	05-01-2015		US
Paclitaxel	injection, solution	6 mg/mL	intravenous	02-01-2008		US
Paclitaxel	injection, solution	6 mg/mL	intravenous	08-05-2002		US

---

Over the Counter Products: Not Available

---

International Brands

• No Brands

---

Brand Names

• No Brands

---

Brand Mixtures

Brand Name	Ingredients
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Abraxane	Paclitaxel
Paclitaxel for Injection	Paclitaxel
Apo-paclitaxel Injectable	Paclitaxel
Abraxane for Injectable Suspension	Paclitaxel
Paclitaxel for Injection	Paclitaxel
Paclitaxel for Injection USP	Paclitaxel
Paclitaxel Injection USP	Paclitaxel
Paclitaxel Injection USP	Paclitaxel
Taxol	Paclitaxel
Paclitaxel Injection	Paclitaxel
Paclitaxel Injection	Paclitaxel
Paxene	Paclitaxel
Paclitaxel for Injection	Paclitaxel
Paclitaxel Injection, USP	Paclitaxel
Paclitaxel	Paclitaxel
Teva-paclitaxel for Injection	Paclitaxel
Aj-paclitaxel	Paclitaxel

Brand Name	Ingredients
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Paclitaxel	Paclitaxel
Abraxane	Paclitaxel
Paclitaxel for Injection	Paclitaxel
Apo-paclitaxel Injectable	Paclitaxel
Abraxane for Injectable Suspension	Paclitaxel
Paclitaxel for Injection	Paclitaxel
Paclitaxel for Injection USP	Paclitaxel
Paclitaxel Injection USP	Paclitaxel
Paclitaxel Injection USP	Paclitaxel
Taxol	Paclitaxel
Paclitaxel Injection	Paclitaxel
Paclitaxel Injection	Paclitaxel
Paxene	Paclitaxel
Paclitaxel for Injection	Paclitaxel
Paclitaxel Injection, USP	Paclitaxel
Paclitaxel	Paclitaxel
Teva-paclitaxel for Injection	Paclitaxel
Aj-paclitaxel	Paclitaxel

---

Categories

• Antineoplastic Agents, Phytogenic
• Tubulin Modulators
• Taxane Derivatives

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

---

Pharmacodynamics: Not Available

---

Mechanism of action: Paclitaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, paclitaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, paclitaxel binds to the β subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of paclitaxel locks these building blocks in place. The resulting microtubule/paclitaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that paclitaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function.

---

Absorption: When a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the maximum plasma concentration (Cmax) is 195 ng/mL, while the AUC is 6300 ng•h/mL.

---

Volume of distribution:

• 227 to 688 L/m^2 [apparent volume of distribution at steady-state, 24 hour infusion]

---

Protein binding: 89%-98% bound to plasma protein. The presence of cimetidine, ranitidine, dexamethasone, or diphenhydramine did not affect protein binding of paclitaxel.

---

Metabolism: Not Available

---

Route of elimination: In 5 patients administered a 225 or 250 mg/m2 dose of radiolabeled paclitaxel as a 3-hour infusion, a mean of 71% of the radioactivity was excreted in the feces in 120 hours, and 14% was recovered in the urine.

---

Half life: When a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the elimination half=life is 52.7 hours.

---

Clearance: Not Available

---

Toxicity: Rat (ipr) LD₅₀=32530 µg/kg. Symptoms of overdose include bone marrow suppression, peripheral neurotoxicity, and mucositis. Overdoses in pediatric patients may be associated with acute ethanol toxicity.

---

Affected organisms

• Not Available

---

SNP Mediated Adverse Drug Reactions

• Not Available

Manufacturers:

• Not Available

---

Packagers:

• Abraxis BioScience Inc.
• Accord Healthcare
• APP Pharmaceuticals
• Barr Pharmaceuticals
• Bedford Labs
• Ben Venue Laboratories Inc.
• Bristol-Myers Squibb Co.
• Ebewe Pharma
• Ethex Corp.
• Fresenius Kabi AB
• Hospira Inc.
• Intas Pharmaceuticals Ltd.
• Ivax Pharmaceuticals
• Mead Johnson and Co.
• Pharmachemie BV
• Pliva Inc.
• Teva Pharmaceutical Industries Ltd.
• UDL Laboratories

---

Dosage forms

Form	Route	Strength
Injection, powder, lyophilized, for suspension	intravenous	100 mg/20mL
Powder for suspension	intravenous	100 mg
Injection	intravenous	100 mg/16.7mL
Injection	intravenous	30 mg/5mL
Injection	intravenous	300 mg/50mL
Injection	intravenous	6 mg/mL
Injection, solution	intravenous	6 mg/mL
Injection, solution, concentrate	intravenous	6 mg/mL
Solution	intravenous	6 mg
Liquid	intravenous	6 mg

Form	Route	Strength
Injection, powder, lyophilized, for suspension	intravenous	100 mg/20mL
Powder for suspension	intravenous	100 mg
Injection	intravenous	100 mg/16.7mL
Injection	intravenous	30 mg/5mL
Injection	intravenous	300 mg/50mL
Injection	intravenous	6 mg/mL
Injection, solution	intravenous	6 mg/mL
Injection, solution, concentrate	intravenous	6 mg/mL
Solution	intravenous	6 mg
Liquid	intravenous	6 mg

---

Prices

Unit description	Cost	Unit
Paclitaxel 150 mg/25 ml vial	$3.36	ml
Paclitaxel 30 mg/5 ml vial	$3.54	ml
Paclitaxel 100 mg/16.7 ml vial	$4.45	ml
Paclitaxel 300 mg/50 ml vial	$5.31	ml
Onxol 30 mg/5 ml vial	$34.54	ml
Onxol 300 mg/50 ml vial	$34.54	ml
Taxol 30 mg/5 ml vial	$35.06	ml
Abraxane 100 mg vial	$1119.6	vial

Unit description	Cost	Unit
Paclitaxel 150 mg/25 ml vial	$3.36	ml
Paclitaxel 30 mg/5 ml vial	$3.54	ml
Paclitaxel 100 mg/16.7 ml vial	$4.45	ml
Paclitaxel 300 mg/50 ml vial	$5.31	ml
Onxol 30 mg/5 ml vial	$34.54	ml
Onxol 300 mg/50 ml vial	$34.54	ml
Taxol 30 mg/5 ml vial	$35.06	ml
Abraxane 100 mg vial	$1119.6	vial

---

Patents

Country	Patent Number	Approved	Expires (estimated)
2086874	Canada	1998-09-01	2013-01-07
2155947	Canada	2007-08-21	2014-02-22
5439686	United States	1993-02-22	2013-02-22
5498421	United States	1993-03-12	2013-03-12

Drug Interactions

Drug	Interaction
Abiraterone	The serum concentration of Paclitaxel can be increased when it is combined with Abiraterone.
Aprepitant	The serum concentration of Paclitaxel can be increased when it is combined with Aprepitant.
Aripiprazole	The serum concentration of Aripiprazole can be decreased when it is combined with Paclitaxel.
Atazanavir	The serum concentration of Paclitaxel can be increased when it is combined with Atazanavir.
Bexarotene	The serum concentration of Bexarotene can be increased when it is combined with Paclitaxel.
Bosentan	The serum concentration of Paclitaxel can be decreased when it is combined with Bosentan.
Carboplatin	Carboplatin may increase the myelosuppressive activities of Paclitaxel.
Cisplatin	Cisplatin may increase the myelosuppressive activities of Paclitaxel.
Clozapine	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Clozapine.
Conivaptan	The serum concentration of Paclitaxel can be increased when it is combined with Conivaptan.
Dabrafenib	The serum concentration of Paclitaxel can be decreased when it is combined with Dabrafenib.
Dasatinib	The serum concentration of Paclitaxel can be increased when it is combined with Dasatinib.
Daunorubicin	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Daunorubicin.
Deferasirox	The serum concentration of Paclitaxel can be decreased when it is combined with Deferasirox.
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Paclitaxel.
Doxorubicin	The metabolism of Doxorubicin can be decreased when combined with Paclitaxel.
Epirubicin	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Epirubicin.
Fluconazole	The metabolism of Paclitaxel can be decreased when combined with Fluconazole.
Fosaprepitant	The serum concentration of Paclitaxel can be increased when it is combined with Fosaprepitant.
Fusidic Acid	The serum concentration of Paclitaxel can be increased when it is combined with Fusidic Acid.
Hydrocodone	The serum concentration of Hydrocodone can be decreased when it is combined with Paclitaxel.
Idarubicin	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Idarubicin.
Idelalisib	The serum concentration of Paclitaxel can be increased when it is combined with Idelalisib.
Ivacaftor	The serum concentration of Paclitaxel can be increased when it is combined with Ivacaftor.
Leflunomide	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Leflunomide.
Luliconazole	The serum concentration of Paclitaxel can be increased when it is combined with Luliconazole.
Metamizole	The risk or severity of adverse effects can be increased when Metamizole is combined with Paclitaxel.
Mifepristone	The serum concentration of Paclitaxel can be increased when it is combined with Mifepristone.
Mitotane	The serum concentration of Paclitaxel can be decreased when it is combined with Mitotane.
Mitoxantrone	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Mitoxantrone.
Natalizumab	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Natalizumab.
Nelfinavir	The metabolism of Paclitaxel can be decreased when combined with Nelfinavir.
Netupitant	The serum concentration of Paclitaxel can be increased when it is combined with Netupitant.
Nimodipine	The serum concentration of Nimodipine can be decreased when it is combined with Paclitaxel.
Oxaliplatin	Oxaliplatin may increase the myelosuppressive activities of Paclitaxel.
Palbociclib	The serum concentration of Paclitaxel can be increased when it is combined with Palbociclib.
Phenytoin	The metabolism of Paclitaxel can be increased when combined with Phenytoin.
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Paclitaxel.
Ranolazine	The serum concentration of Paclitaxel can be increased when it is combined with Ranolazine.
Ritonavir	The metabolism of Paclitaxel can be decreased when combined with Ritonavir.
Roflumilast	Roflumilast may increase the immunosuppressive activities of Paclitaxel.
Rosiglitazone	The metabolism of Paclitaxel can be decreased when combined with Rosiglitazone.
Saquinavir	The serum concentration of Paclitaxel can be increased when it is combined with Saquinavir.
Saxagliptin	The serum concentration of Saxagliptin can be decreased when it is combined with Paclitaxel.
Siltuximab	The serum concentration of Paclitaxel can be decreased when it is combined with Siltuximab.
Simeprevir	The serum concentration of Paclitaxel can be increased when it is combined with Simeprevir.
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Paclitaxel.
Sorafenib	The risk or severity of adverse effects can be increased when Sorafenib is combined with Paclitaxel.
St. John's Wort	The serum concentration of Paclitaxel can be decreased when it is combined with St. John's Wort.
Stiripentol	The serum concentration of Paclitaxel can be increased when it is combined with Stiripentol.
Tacrolimus	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Paclitaxel.
Tesmilifene	The serum concentration of Paclitaxel can be decreased when it is combined with Tesmilifene.
Tocilizumab	The serum concentration of Paclitaxel can be decreased when it is combined with Tocilizumab.
Tofacitinib	Paclitaxel may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab	The serum concentration of Paclitaxel can be decreased when it is combined with Trastuzumab.
Trimethoprim	The metabolism of Paclitaxel can be decreased when combined with Trimethoprim.
Verapamil	The serum concentration of Paclitaxel can be increased when it is combined with Verapamil.
Vinorelbine	Paclitaxel may increase the neurotoxic activities of Vinorelbine.

Drug	Interaction
Abiraterone	The serum concentration of Paclitaxel can be increased when it is combined with Abiraterone.
Aprepitant	The serum concentration of Paclitaxel can be increased when it is combined with Aprepitant.
Aripiprazole	The serum concentration of Aripiprazole can be decreased when it is combined with Paclitaxel.
Atazanavir	The serum concentration of Paclitaxel can be increased when it is combined with Atazanavir.
Bexarotene	The serum concentration of Bexarotene can be increased when it is combined with Paclitaxel.
Bosentan	The serum concentration of Paclitaxel can be decreased when it is combined with Bosentan.
Carboplatin	Carboplatin may increase the myelosuppressive activities of Paclitaxel.
Cisplatin	Cisplatin may increase the myelosuppressive activities of Paclitaxel.
Clozapine	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Clozapine.
Conivaptan	The serum concentration of Paclitaxel can be increased when it is combined with Conivaptan.
Dabrafenib	The serum concentration of Paclitaxel can be decreased when it is combined with Dabrafenib.
Dasatinib	The serum concentration of Paclitaxel can be increased when it is combined with Dasatinib.
Daunorubicin	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Daunorubicin.
Deferasirox	The serum concentration of Paclitaxel can be decreased when it is combined with Deferasirox.
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Paclitaxel.
Doxorubicin	The metabolism of Doxorubicin can be decreased when combined with Paclitaxel.
Epirubicin	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Epirubicin.
Fluconazole	The metabolism of Paclitaxel can be decreased when combined with Fluconazole.
Fosaprepitant	The serum concentration of Paclitaxel can be increased when it is combined with Fosaprepitant.
Fusidic Acid	The serum concentration of Paclitaxel can be increased when it is combined with Fusidic Acid.
Hydrocodone	The serum concentration of Hydrocodone can be decreased when it is combined with Paclitaxel.
Idarubicin	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Idarubicin.
Idelalisib	The serum concentration of Paclitaxel can be increased when it is combined with Idelalisib.
Ivacaftor	The serum concentration of Paclitaxel can be increased when it is combined with Ivacaftor.
Leflunomide	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Leflunomide.
Luliconazole	The serum concentration of Paclitaxel can be increased when it is combined with Luliconazole.
Metamizole	The risk or severity of adverse effects can be increased when Metamizole is combined with Paclitaxel.
Mifepristone	The serum concentration of Paclitaxel can be increased when it is combined with Mifepristone.
Mitotane	The serum concentration of Paclitaxel can be decreased when it is combined with Mitotane.
Mitoxantrone	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Mitoxantrone.
Natalizumab	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Natalizumab.
Nelfinavir	The metabolism of Paclitaxel can be decreased when combined with Nelfinavir.
Netupitant	The serum concentration of Paclitaxel can be increased when it is combined with Netupitant.
Nimodipine	The serum concentration of Nimodipine can be decreased when it is combined with Paclitaxel.
Oxaliplatin	Oxaliplatin may increase the myelosuppressive activities of Paclitaxel.
Palbociclib	The serum concentration of Paclitaxel can be increased when it is combined with Palbociclib.
Phenytoin	The metabolism of Paclitaxel can be increased when combined with Phenytoin.
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Paclitaxel.
Ranolazine	The serum concentration of Paclitaxel can be increased when it is combined with Ranolazine.
Ritonavir	The metabolism of Paclitaxel can be decreased when combined with Ritonavir.
Roflumilast	Roflumilast may increase the immunosuppressive activities of Paclitaxel.
Rosiglitazone	The metabolism of Paclitaxel can be decreased when combined with Rosiglitazone.
Saquinavir	The serum concentration of Paclitaxel can be increased when it is combined with Saquinavir.
Saxagliptin	The serum concentration of Saxagliptin can be decreased when it is combined with Paclitaxel.
Siltuximab	The serum concentration of Paclitaxel can be decreased when it is combined with Siltuximab.
Simeprevir	The serum concentration of Paclitaxel can be increased when it is combined with Simeprevir.
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Paclitaxel.
Sorafenib	The risk or severity of adverse effects can be increased when Sorafenib is combined with Paclitaxel.
St. John's Wort	The serum concentration of Paclitaxel can be decreased when it is combined with St. John's Wort.
Stiripentol	The serum concentration of Paclitaxel can be increased when it is combined with Stiripentol.
Tacrolimus	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Paclitaxel.
Tesmilifene	The serum concentration of Paclitaxel can be decreased when it is combined with Tesmilifene.
Tocilizumab	The serum concentration of Paclitaxel can be decreased when it is combined with Tocilizumab.
Tofacitinib	Paclitaxel may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab	The serum concentration of Paclitaxel can be decreased when it is combined with Trastuzumab.
Trimethoprim	The metabolism of Paclitaxel can be decreased when combined with Trimethoprim.
Verapamil	The serum concentration of Paclitaxel can be increased when it is combined with Verapamil.
Vinorelbine	Paclitaxel may increase the neurotoxic activities of Vinorelbine.

---

Food Interactions:

• Avoid echinacea.
• Avoid grapefruit and grapefruit juice due to potential increase of paclitaxel.

Kingdom: Organic compounds

---

Super Class: Not Available

---

Class: Not Available

---

Sub Class: Not Available

---

Direct Parent: Not Available

---

Alternative Parents:

• Acetate salts
• Alpha-acyloxy ketones
• Benzoic acid esters
• Benzoyl derivatives
• Benzylethers
• Beta amino acids and derivatives
• Carboxylic acid esters
• Cyclic alcohols and derivatives
• Dialkyl ethers
• Dicarboxylic acids and derivatives
• Fatty acid esters
• Hydrocarbon derivatives
• Ketones
• Monosaccharides
• N-benzylbenzamides
• Organonitrogen compounds
• Oxacyclic compounds
• Oxetanes
• Phenylpropylamines
• Secondary alcohols
• Secondary carboxylic acid amides
• Tertiary alcohols

---

substituent:

• Acetate salt
• Alcohol
• Alpha-acyloxy ketone
• Aromatic heteropolycyclic compound
• Benzamide
• Benzenoid
• Benzoate ester
• Benzoic acid or derivatives
• Benzoyl
• Benzylether
• Beta amino acid or derivatives
• Carbonyl group
• Carboxamide group
• Carboxylic acid derivative
• Carboxylic acid ester
• Cyclic alcohol
• Dialkyl ether
• Dicarboxylic acid or derivatives
• Ether
• Fatty acid ester
• Fatty acyl
• Hydrocarbon derivative
• Ketone
• Monocyclic benzene moiety
• Monosaccharide
• N-benzylbenzamide
• Organoheterocyclic compound
• Organonitrogen compound
• Organooxygen compound
• Oxacycle
• Oxetane
• Phenylpropylamine
• Secondary alcohol
• Secondary carboxylic acid amide
• Taxane diterpenoid
• Tertiary alcohol

Synthesis Reference: Hendricus B. A. de Bont, Ruben G. G. Leenders, Johan W. Scheeren, Hidde J. Haisma, Dick de Vos, "Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy." U.S. Patent US5760072, issued September, 1989.

---

General Reference: # Wall ME, Wani MC: Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 1995 Feb 15;55(4):753-60. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7850785 # Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT: Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971 May 5;93(9):2325-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/5553076 # Fuchs DA, Johnson RK: Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep. 1978 Aug;62(8):1219-22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/688258 # Saville MW, Lietzau J, Pluda JM, Feuerstein I, Odom J, Wilson WH, Humphrey RW, Feigal E, Steinberg SM, Broder S, et al.: Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet. 1995 Jul 1;346(8966):26-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7603142 # ABI 007. Drugs R D. 2004;5(3):155-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15139776 # Gaitanis A, Staal S: Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use. Methods Mol Biol. 2010;624:385-92. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20217610

---

External Links:

Resource	Link
RxList	http://www.rxlist.com/cgi/generic/paclitaxel.htm
Drugs.com	http://www.drugs.com/cdi/paclitaxel.html

Resource	Link
RxList	http://www.rxlist.com/cgi/generic/paclitaxel.htm
Drugs.com	http://www.drugs.com/cdi/paclitaxel.html

---

ATC Codes:

• Array

---

AHFS Codes:

• 10:00.00

---

MSDS: Download